$MCRB
Seres Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023006374 Filed on March 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue -$522.0K $975.0K $7.128M
YoY Change -134.96% -86.5% -95.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.47M $22.40M $85.80M
YoY Change 21.0% 9.26% 23.87%
% of Gross Profit
Research & Development $43.97M $46.22M $172.9M
YoY Change 10.9% 25.76% 21.87%
% of Gross Profit
Depreciation & Amortization $1.400M $1.627M $6.629M
YoY Change -10.83% 4.83% 11.47%
% of Gross Profit
Operating Expenses $70.05M $69.28M $253.6M
YoY Change 22.36% 22.29% 21.1%
Operating Profit -$70.57M -$246.5M
YoY Change 26.58% 282.2%
Interest Expense -$916.0K -$466.0K -$2.962M
YoY Change 73.48% 84.19% 7305.0%
% of Operating Profit
Other Income/Expense, Net -$606.0K -$23.00K -$3.667M
YoY Change -30.58% -92.72% 237.97%
Pretax Income -$71.17M -$68.80M -$250.2M
YoY Change 25.7% 37.59% 281.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$71.17M -$68.80M -$250.2M
YoY Change 25.7% 37.59% 281.46%
Net Earnings / Revenue -7056.0% -3509.5%
Basic Earnings Per Share -$0.57 -$2.31
Diluted Earnings Per Share -$0.57 -$0.55 -$2.31
COMMON SHARES
Basic Shares Outstanding 126.1M 124.6M 108.1M
Diluted Shares Outstanding 125.9M 108.1M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.5M $181.3M $181.3M
YoY Change -57.04% -37.62% -37.62%
Cash & Equivalents $94.84M $163.0M $163.0M
Short-Term Investments $11.70M $18.31M $18.31M
Other Short-Term Assets $9.537M $13.42M $13.42M
YoY Change -37.46% 3.88% 3.88%
Inventory $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $116.1M $194.8M $194.8M
YoY Change -55.9% -35.85% -35.85%
LONG-TERM ASSETS
Property, Plant & Equipment $24.31M $22.99M $134.0M
YoY Change 27.48% 28.14% 270.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $11.31M $10.47M $20.05M
YoY Change 549.45% 101.68% 37.43%
Total Long-Term Assets $154.1M $154.0M $154.0M
YoY Change 172.1% 200.64% 200.64%
TOTAL ASSETS
Total Short-Term Assets $116.1M $194.8M $194.8M
Total Long-Term Assets $154.1M $154.0M $154.0M
Total Assets $270.2M $348.8M $348.8M
YoY Change -15.54% -1.71% -1.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.30M $17.44M $17.44M
YoY Change 81.08% 26.97% 26.97%
Accrued Expenses $11.66M $18.31M $18.31M
YoY Change -3.94% 15.7% 15.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $456.0K $456.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.82M $85.60M $85.60M
YoY Change -22.51% 4.06% 4.06%
LONG-TERM LIABILITIES
Long-Term Debt $51.23M $50.59M $50.59M
YoY Change 1.58% 105.3% 105.3%
Other Long-Term Liabilities $1.486M $1.442M $201.8M
YoY Change -61.98% -87.46% 73.3%
Total Long-Term Liabilities $1.486M $1.442M $252.4M
YoY Change -61.98% -87.46% 78.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.82M $85.60M $85.60M
Total Long-Term Liabilities $1.486M $1.442M $252.4M
Total Liabilities $318.1M $338.0M $338.0M
YoY Change 33.12% 51.33% 51.33%
SHAREHOLDERS EQUITY
Retained Earnings -$935.7M -$864.5M
YoY Change 39.45% 40.72%
Common Stock $887.8M $875.3M
YoY Change 18.04% 17.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$47.87M $10.78M $10.78M
YoY Change
Total Liabilities & Shareholders Equity $270.2M $348.8M $348.8M
YoY Change -15.54% -1.71% -1.71%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$71.17M -$68.80M -$250.2M
YoY Change 25.7% 37.59% 281.46%
Depreciation, Depletion And Amortization $1.400M $1.627M $6.629M
YoY Change -10.83% 4.83% 11.47%
Cash From Operating Activities -$76.58M -$52.89M -$228.8M
YoY Change 15.26% 1.99% -3521.29%
INVESTING ACTIVITIES
Capital Expenditures $4.068M $3.461M $9.821M
YoY Change 37.9% -319.33% 2.67%
Acquisitions
YoY Change
Other Investing Activities $6.807M $9.387M $92.25M
YoY Change -57.25% -36.42% 25.25%
Cash From Investing Activities $2.739M $5.926M $82.43M
YoY Change -78.89% -55.06% 28.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $96.72M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.656M 4.597M 129.6M
YoY Change -78.93% -689.36% 10901.87%
NET CHANGE
Cash From Operating Activities -76.58M -52.89M -228.8M
Cash From Investing Activities 2.739M 5.926M 82.43M
Cash From Financing Activities 5.656M 4.597M 129.6M
Net Change In Cash -68.19M -42.37M -16.79M
YoY Change 156.11% 7.38% -123.33%
FREE CASH FLOW
Cash From Operating Activities -$76.58M -$52.89M -$228.8M
Capital Expenditures $4.068M $3.461M $9.821M
Free Cash Flow -$80.65M -$56.35M -$238.6M
YoY Change 16.22% 12.07% 8191.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001609809
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37465
CY2022 dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street – 4th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
945-9626
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
MCRB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
239918450
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126076391
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
18311000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
110704000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13423000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12922000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
194764000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
303628000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
495000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10465000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5189000
CY2022Q4 us-gaap Assets
Assets
348784000
CY2021Q4 us-gaap Assets
Assets
354859000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17440000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13735000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
456000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
4259000
CY2021Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
16819000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85596000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82258000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
50591000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24643000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2022Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
92430000
CY2021Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
86998000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1442000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11495000
CY2022Q4 us-gaap Liabilities
Liabilities
338001000
CY2021Q4 us-gaap Liabilities
Liabilities
223352000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125222273
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125222273
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91889418
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91889418
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
92000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
875181000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
745829000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-864511000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614354000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348784000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354859000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
34770000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21098000
CY2022Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
10585000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7128000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
143857000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11897000
CY2022 mcrb Revenue From Grant
RevenueFromGrant
0
CY2021 mcrb Revenue From Grant
RevenueFromGrant
1070000
CY2020 mcrb Revenue From Grant
RevenueFromGrant
4157000
CY2022 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
0
CY2021 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
0
CY2020 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
17161000
CY2022 us-gaap Revenues
Revenues
7128000
CY2021 us-gaap Revenues
Revenues
144927000
CY2020 us-gaap Revenues
Revenues
33215000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172920000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141891000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90570000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
79694000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
69261000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30775000
CY2022 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
1004000
CY2021 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
-1732000
CY2020 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
253618000
CY2021 us-gaap Operating Expenses
OperatingExpenses
209420000
CY2020 us-gaap Operating Expenses
OperatingExpenses
121345000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-246490000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-64493000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-88130000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3058000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
2870000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
946000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
6020000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
2910000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
2924000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-705000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1045000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
981000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3667000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1085000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-997000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-250157000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108077043
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108077043
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91702866
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91702866
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79789220
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79789220
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
49000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
48000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-250109000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65591000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89174000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243748000
CY2020 mcrb Stock Issued During Period To Related Party Value
StockIssuedDuringPeriodToRelatedPartyValue
19900000
CY2020 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
24773000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14421000
CY2020 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
462000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8824000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-47000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1299000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
827000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20222000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-13000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
966000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1769000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3279000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96721000
CY2022 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4447000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25482000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
48000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-250157000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-250157000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
25482000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
20222000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
8824000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6629000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5947000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6578000
CY2022 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
5224000
CY2021 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
3275000
CY2020 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2315000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-688000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-498000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-446000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
705000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2526000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
551000
CY2022 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-1004000
CY2021 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1732000
CY2020 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
0
CY2022 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-12599000
CY2021 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-12337000
CY2020 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-2186000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9387000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7602000
CY2022 mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-7128000
CY2021 mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-4357000
CY2020 mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-11565000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2203000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9362000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1159000
CY2022 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4203000
CY2021 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3550000
CY2020 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4456000
CY2022 mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
3336000
CY2021 mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
43025000
CY2020 mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
3771000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-228816000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6688000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93610000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9821000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9566000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
591000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
48221000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95971000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
218284000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
140470000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
169625000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
59984000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82428000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64088000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158891000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
96721000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
243748000
CY2022 mcrb Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party
ProceedsFromSecuritiesPurchaseAgreementNetOfIssuanceCostsRelatedParty
0
CY2021 mcrb Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party
ProceedsFromSecuritiesPurchaseAgreementNetOfIssuanceCostsRelatedParty
0
CY2020 mcrb Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party
ProceedsFromSecuritiesPurchaseAgreementNetOfIssuanceCostsRelatedParty
19900000
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
27606000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2022 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
4447000
CY2021 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
0
CY2020 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
24773000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
966000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1299000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14421000
CY2022 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
0
CY2021 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
0
CY2020 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1769000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
827000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
462000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1907000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
948000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129602000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1178000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
303424000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16786000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
71954000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
50923000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
4926000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2446000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2453000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2276000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
874000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
451000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
91412000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12442000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022 mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
6822000
CY2021 mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
0
CY2020 mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
0
CY2022 mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
3087000
CY2021 mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
31683000
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-864511000
CY2022Q4 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
181341000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-250157000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-228816000
CY2022Q4 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q4 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In these consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></p>
CY2022 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2022 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has all cash, cash equivalents and investments balances at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 mcrb Revenue Recognized Related To Sales Based Royalties
RevenueRecognizedRelatedToSalesBasedRoyalties
0
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
CY2022 mcrb Minimum Percentage Of Likelihood Of Tax Benefit Being Realized Upon Settlement
MinimumPercentageOfLikelihoodOfTaxBenefitBeingRealizedUponSettlement
0.50
CY2021Q4 mcrb Fair Values Assets Level1 To Level2 Transfer Amount1
FairValuesAssetsLevel1ToLevel2TransferAmount1
0
CY2022Q4 mcrb Fair Values Assets Level1 To Level2 Transfer Amount1
FairValuesAssetsLevel1ToLevel2TransferAmount1
0
CY2021Q4 mcrb Fair Values Assets Level2 To Level1 Transfer Amount1
FairValuesAssetsLevel2ToLevel1TransferAmount1
0
CY2022Q4 mcrb Fair Values Assets Level2 To Level1 Transfer Amount1
FairValuesAssetsLevel2ToLevel1TransferAmount1
0
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18321000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18311000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
59000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2022 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2021 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2020 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
18321000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
18311000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18321000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18311000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
110762000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
110704000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
496000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
495000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2022Q4 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
34770000
CY2021Q4 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
21098000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3644000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3633000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5900000
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from approximately one year to five years.
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
56065000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
54206000
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68025000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58206000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45040000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40268000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6629000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5947000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6578000
CY2022 mcrb Disposal Of Fully Depreciated Assets Cost Basis
DisposalOfFullyDepreciatedAssetsCostBasis
1857000
CY2022Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
6717000
CY2021Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
11147000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14709000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9216000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2327000
CY2021Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
3573000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2021Q3 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
770000
CY2021Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1859000
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q2 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
1223000
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
452000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
111543000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24568000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
8830000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
5170000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4163000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1375000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1452000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1457000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
4547000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
3300000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2890000
CY2022 mcrb Sublease Income1
SubleaseIncome1
0
CY2021 mcrb Sublease Income1
SubleaseIncome1
-1575000
CY2020 mcrb Sublease Income1
SubleaseIncome1
-1813000
CY2022 us-gaap Lease Cost
LeaseCost
14752000
CY2021 us-gaap Lease Cost
LeaseCost
8347000
CY2020 us-gaap Lease Cost
LeaseCost
6697000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
7809000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
6821000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
6302000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28007000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4527897
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16815000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19055000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
21164000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
21755000
CY2022Q4 mcrb Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
108383000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
187172000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
75629000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
111543000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y11M1D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.13
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M13D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
50000000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
50000000
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8738243
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11517189
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.89
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.96
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
326864
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.03
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
778188
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.62
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14940034
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89127000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108077043
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11608000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7441253
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.38
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8115000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.33
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.08
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
981000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4727000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
37255000
CY2021 mcrb Number Of Employees Granted
NumberOfEmployeesGranted
2
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25482000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20222000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8824000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
57005000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2022 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
7128000
CY2021 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
10446000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-250157000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65578000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108077043
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91702866
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91702866
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79789220
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79789220
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.31
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.31
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16579167
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12416991
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10054416
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.031
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.166
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.064
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.078
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.058
CY2022 mcrb Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves
0.046
CY2021 mcrb Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves
0
CY2020 mcrb Effective Income Tax Rate Reconciliation Uncertain Tax Position Reserves
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionReserves
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.404
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.408
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
132560000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
108189000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
48854000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
53133000
CY2022Q4 mcrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
38894000
CY2021Q4 mcrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
20048000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
16045000
CY2022Q4 mcrb Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
29717000
CY2021Q4 mcrb Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6635000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
29922000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
36666000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4044000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2475000
CY2022Q4 mcrb Deferred Tax Assets Section163 J Limitation Cares Act
DeferredTaxAssetsSection163JLimitationCARESAct
2303000
CY2021Q4 mcrb Deferred Tax Assets Section163 J Limitation Cares Act
DeferredTaxAssetsSection163JLimitationCARESAct
1368000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
396000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
247000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
200000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
274000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
306938000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
225032000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2022Q4 mcrb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
29568000
CY2021Q4 mcrb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
4918000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
29568000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4918000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
277370000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220114000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
160586000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220114000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193736000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
157346000
CY2022 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
57256000
CY2021 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
26378000
CY2020 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
36390000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
277370000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220114000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193736000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
12528000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
12528000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8738243
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
3.15
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27525000
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1921000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1087000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
586000

Files In Submission

Name View Source Status
0000950170-23-006374-index-headers.html Edgar Link pending
0000950170-23-006374-index.html Edgar Link pending
0000950170-23-006374.txt Edgar Link pending
0000950170-23-006374-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img113832420_0.jpg Edgar Link pending
mcrb-20221231.htm Edgar Link pending
mcrb-20221231.xsd Edgar Link pending
mcrb-ex10_1.htm Edgar Link pending
mcrb-ex10_28.htm Edgar Link pending
mcrb-ex10_4.htm Edgar Link pending
mcrb-ex10_5.htm Edgar Link pending
mcrb-ex23_1.htm Edgar Link pending
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
mcrb-20221231_cal.xml Edgar Link unprocessable
mcrb-20221231_pre.xml Edgar Link unprocessable
mcrb-20221231_lab.xml Edgar Link unprocessable
mcrb-20221231_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mcrb-20221231_def.xml Edgar Link unprocessable